mRNA Vaccine for Deadly Nipah Virus Shows Strong Immune Response in Phase 1 Trial

The mRNA Platform Advantage

The mRNA-1215 vaccine encodes a chimeric pre-fusion form of the Nipah virus fusion protein (F protein) linked to the attachment glycoprotein (G), a design intended to generate immune responses against the structures the virus uses to enter human cells. By targeting both proteins together in a stabilized pre-fusion form, the vaccine aims to maximize the breadth and potency of the immune response.

The mRNA platform enables rapid design iteration—if new Nipah strains emerge with mutations in the target proteins, the vaccine sequence can theoretically be updated and new doses produced within weeks, a capability that proved valuable during the COVID-19 pandemic's successive variant waves. This adaptability is a major argument for mRNA-based pandemic preparedness strategies.

Phase 1 Trial Results

The phase 1 trial was an open-label dose-escalation study conducted in healthy adults, the standard design for first-in-human vaccine safety evaluation. Participants received the vaccine at various doses and were monitored for safety signals—adverse reactions, lab abnormalities, and clinical events—and for immune response, measured by antibody levels and cellular immunity markers.

The trial found that mRNA-1215 was well tolerated, with adverse events generally mild to moderate and consistent with those seen with other mRNA vaccines. More significantly, the vaccine induced elevated immune responses against Nipah virus antigens, with antibody levels remaining measurably elevated at the one-year follow-up visit—the longest timepoint assessed in the trial.

What Comes Next

Phase 1 trials are primarily designed to demonstrate safety and generate initial immunogenicity data; they are not powered to demonstrate protection against actual infection. The next step would typically be a phase 2 trial with larger numbers of participants and more detailed immunogenicity assessments, followed potentially by a phase 3 efficacy trial.

Conducting a phase 3 efficacy trial for Nipah presents logistical challenges because the virus is endemic only in parts of Asia and outbreaks are unpredictable. Regulators may allow approval under accelerated pathways used for other emergency countermeasures if immunogenicity data correlate sufficiently well with protection—a model used for some Ebola and anthrax vaccines.

Pandemic Preparedness Investment

The Nipah vaccine effort reflects a broader shift in pandemic preparedness strategy following COVID-19. The Coalition for Epidemic Preparedness Innovations (CEPI), which has funded Nipah vaccine development including the mRNA-1215 program, was created after the West Africa Ebola outbreak to accelerate countermeasures against priority pathogens before outbreaks become pandemics.

Having a vaccine candidate with demonstrated safety and immunogenicity in the freezer—ready for rapid scale-up if a Nipah outbreak begins to spread internationally—is exactly the kind of preparedness investment CEPI was designed to enable. The phase 1 results position mRNA-1215 as one of the most advanced Nipah vaccine candidates to date.

This article is based on reporting by Nature Medicine. Read the original article.